[
  {
    "ts": null,
    "headline": "Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025",
    "summary": "The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive opportunities for investors.",
    "url": "https://finnhub.io/api/news?id=5893587e5fa3e91a37b6975c5ceac34f7fc311555b4dc90278e6109cce22d835",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736791802,
      "headline": "Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025",
      "id": 132390023,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1886168184/image_1886168184.jpg?io=getty-c-w1536",
      "related": "INCY",
      "source": "SeekingAlpha",
      "summary": "The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive opportunities for investors.",
      "url": "https://finnhub.io/api/news?id=5893587e5fa3e91a37b6975c5ceac34f7fc311555b4dc90278e6109cce22d835"
    }
  },
  {
    "ts": null,
    "headline": "Has Incyte (INCY) Outpaced Other Medical Stocks This Year?",
    "summary": "Here is how Incyte (INCY) and Atara Biotherapeutics (ATRA) have performed compared to their sector so far this year.",
    "url": "https://finnhub.io/api/news?id=b505a43bd246c653677be39052a2762a235f58513479ae4e2ed0308bdbb02295",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736779244,
      "headline": "Has Incyte (INCY) Outpaced Other Medical Stocks This Year?",
      "id": 132416874,
      "image": "https://media.zenfs.com/en/zacks.com/a41b81fe729c761f3f94f42ff348f70c",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Here is how Incyte (INCY) and Atara Biotherapeutics (ATRA) have performed compared to their sector so far this year.",
      "url": "https://finnhub.io/api/news?id=b505a43bd246c653677be39052a2762a235f58513479ae4e2ed0308bdbb02295"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference",
    "summary": "WILMINGTON, Del., January 13, 2025--Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference",
    "url": "https://finnhub.io/api/news?id=786b880de68f7185c4698ea334b92bebb7862793737c7064b03d61eed81f294f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736775000,
      "headline": "Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference",
      "id": 132416876,
      "image": "https://media.zenfs.com/en/business-wire.com/787bd5dd194dc40b6947313d8fe96b4a",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "WILMINGTON, Del., January 13, 2025--Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference",
      "url": "https://finnhub.io/api/news?id=786b880de68f7185c4698ea334b92bebb7862793737c7064b03d61eed81f294f"
    }
  }
]